336 Hormonal Replacement Therapy And Health Related Quality Of Life

A. Biscaia, O. Santos
Edideco, Lisboa, Portugal.
Background, Aim:
Hormonal Replacement Therapy (HRT), as a long term treatment, must be safe and effective but also well accepted and either maintain or improve health related quality of life (HRQoL). This is a comparative study on HRQoL associated with HRT drugs and non-HRT drugs for menopausal symptoms relief.
Methods: This is an observational, cross-sectional and multicentre survey sponsored by Conseur (an international consumer’s association). 52 family doctors and Gynaecologists from Portugal, Italy and Belgium selected, from their practices, 1023 post-menopausal women taking the same medication for longer than 6 months. HRQoL was assessed by the MOS’s SF-36 Questionnaire and the MENQol Questionnaire. HRT drugs considered for analysis included Kliogest(R), Estracomb TTS(R), Climen(R), Livial(R), Premarin Plus(R)/Premplus(R), Trisequens(R), Dilena(R)/Diviva(R) and Progyluton(R)/Cyclocur(R). Statistical analysis involved multiple regression analysis and one-way ANOVA followed by post-hoc multiple comparison analyses (at alpha = 0.05).
Results: Women on HRT had significantly better results than the ones on non-HRT treatment for menopausal symptoms relief. Between HRT drugs, Dilena(R)/Diviva(R) had worse results than the others in what SF-36’s Physical Component and Bodily Pain Scales were concerned, and Progyluton(R)/Cyclocur(R) had worse results in the SF-36’s Physical Functioning Scales. In the MENQoL scales, Dilena(R)/Diviva(R) was again worse in the Physical Scale, the “aching in muscles and joints” item and the “difficulty in sleeping” item. In this last item, Progyluton(R)/Cyclocur(R) was also worse than the others.
HRQoL associated to HRT drugs can be assessed in daily-life conditions and may, thus, be taken into account when adjusting drug treatment in each single case.
336 Hormonal Replacement Therapy and Health Related Quality of Life